ATE289586T1 - Oxamsäuren mit einer cyanogruppe als liganden für den thyroidrezeptor - Google Patents
Oxamsäuren mit einer cyanogruppe als liganden für den thyroidrezeptorInfo
- Publication number
- ATE289586T1 ATE289586T1 AT00301104T AT00301104T ATE289586T1 AT E289586 T1 ATE289586 T1 AT E289586T1 AT 00301104 T AT00301104 T AT 00301104T AT 00301104 T AT00301104 T AT 00301104T AT E289586 T1 ATE289586 T1 AT E289586T1
- Authority
- AT
- Austria
- Prior art keywords
- prodrugs
- ligands
- cyano group
- isomers
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
- C07C255/60—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton at least one of the singly-bound nitrogen atoms being acylated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12211999P | 1999-03-01 | 1999-03-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE289586T1 true ATE289586T1 (de) | 2005-03-15 |
Family
ID=22400746
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT00301104T ATE289586T1 (de) | 1999-03-01 | 2000-02-14 | Oxamsäuren mit einer cyanogruppe als liganden für den thyroidrezeptor |
Country Status (10)
Country | Link |
---|---|
US (1) | US6194454B1 (de) |
EP (1) | EP1033364B1 (de) |
JP (1) | JP3564680B2 (de) |
AT (1) | ATE289586T1 (de) |
BR (1) | BR0000968A (de) |
CA (1) | CA2299760C (de) |
DE (1) | DE60018225T2 (de) |
DK (1) | DK1033364T3 (de) |
ES (1) | ES2234523T3 (de) |
PT (1) | PT1033364E (de) |
Families Citing this family (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6790978B2 (en) | 1999-03-29 | 2004-09-14 | Novartis Ag | Thyromimetic organic compounds |
US6599942B1 (en) | 1999-03-29 | 2003-07-29 | Novartis Ag | Thyromimetic organic compounds |
ES2265948T3 (es) * | 1999-06-14 | 2007-03-01 | Cancer Research Technology Limited | Terapia para el cancer. |
ATE295348T1 (de) | 2000-02-17 | 2005-05-15 | Bristol Myers Squibb Co | Thyroid-rezeptorliganden, die von anilin ableitbar sind |
WO2001070687A1 (de) * | 2000-03-23 | 2001-09-27 | Bayer Aktiengesellschaft | Indole zur behandlung von krankheiten die mit schilddrüsenhormonen behandeln werden können |
US6664291B2 (en) | 2000-03-31 | 2003-12-16 | Pfizer, Inc. | Malonamic acids and derivatives thereof as thyroid receptor ligands |
US6395784B1 (en) | 2000-06-07 | 2002-05-28 | Bristol-Myers Squibb Company | Benzamide ligands for the thyroid receptor |
WO2002009700A1 (en) * | 2000-07-28 | 2002-02-07 | Cancer Research Technology Limited | Cancer treatment by combination therapy |
US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
US6555581B1 (en) | 2001-02-15 | 2003-04-29 | Jones Pharma, Inc. | Levothyroxine compositions and methods |
GB0121285D0 (en) * | 2001-09-03 | 2001-10-24 | Cancer Res Ventures Ltd | Anti-cancer combinations |
DE60208132T2 (de) | 2001-09-26 | 2006-07-20 | Pfizer Products Inc., Groton | Indolcaroboxylsäure als Thyroidrezeptor-Liganden |
US6806381B2 (en) * | 2001-11-02 | 2004-10-19 | Bristol-Myers Squibb Company | Process for the preparation of aniline-derived thyroid receptor ligands |
US20030235609A1 (en) * | 2002-01-25 | 2003-12-25 | Lautt Wilfred Wayne | Use of cholinesterase antagonists to treat insulin resistance |
WO2003064369A1 (fr) * | 2002-01-30 | 2003-08-07 | Kissei Pharmaceutical Co., Ltd. | Nouveau ligand de recepteur de l'hormone thyroidienne, preparations medicinales le contenant et leur utilisation |
GB2386836B (en) * | 2002-03-22 | 2006-07-26 | Cancer Res Ventures Ltd | Anti-cancer combinations |
CN100411618C (zh) * | 2002-05-17 | 2008-08-20 | 迪欧加药品公司 | 有效的选择性阿片受体调制剂化合物的用途 |
ATE395936T1 (de) * | 2002-06-20 | 2008-06-15 | Univ Alberta | Dichloracetat in kombination mit kardioprotektiven oder hämodynamischen medikamenten |
BR0314872A (pt) * | 2002-10-18 | 2005-08-02 | Pfizer Prod Inc | Ligandos do receptor canabinóide e usos dos mesmos |
GB2394658A (en) * | 2002-11-01 | 2004-05-05 | Cancer Rec Tech Ltd | Oral anti-cancer composition |
WO2004043459A1 (en) * | 2002-11-12 | 2004-05-27 | Novartis Ag | Treatment of mesothelioma |
KR101102229B1 (ko) * | 2003-05-27 | 2012-01-05 | 닐스 리차드 웰쉬 | 당뇨병을 치료하기 위한 티로신 키나제 억제제의 용도 |
GB0321999D0 (en) * | 2003-09-19 | 2003-10-22 | Cancer Rec Tech Ltd | Anti-cancer combinations |
BRPI0416639A (pt) * | 2003-11-19 | 2007-01-16 | Metabasis Therapeutics Inc | tiromiméticos contendo fósforo |
WO2005073409A2 (en) * | 2004-01-26 | 2005-08-11 | Applera Corporation | Methods, compositions, and kits for amplifying and sequencing polynucleotides |
ES2399721T5 (es) | 2004-03-05 | 2016-05-25 | Univ Pennsylvania | Métodos para tratar trastornos o enfermedades asociados a la hiperlipidemia e hipercolesterolemia minimizando los efectos adversos |
US20050215529A1 (en) * | 2004-03-24 | 2005-09-29 | The Regents Of The University Of Michigan | Method of treating oxidative stress-associated conditions with isopentenyl diphosphate |
WO2006002421A2 (en) | 2004-06-24 | 2006-01-05 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
WO2006004803A1 (en) * | 2004-06-30 | 2006-01-12 | Combinatorx, Incorporated | Methods and reagents for the treatment of metabolic disorders |
US20080260763A1 (en) * | 2004-07-01 | 2008-10-23 | The Regents Of The University Of California | High Throughput Proteomics |
DK1817058T3 (en) * | 2004-11-24 | 2015-12-07 | Hills Pet Nutrition Inc | COMPOSITION FOR USE FOR IMPROVING THE hepatic clearance xenobiotics WITH AN ANIMAL |
US20090176864A1 (en) * | 2004-11-24 | 2009-07-09 | Hill's Pet Nutrition, Inc. | Methods For Improving Hepatic and Immune Function In An Animal |
US8252742B2 (en) | 2004-12-30 | 2012-08-28 | Hill's Pet Nutrition, Inc. | Methods for enhancing the quality of life of a senior animal |
CN102907561A (zh) * | 2004-12-30 | 2013-02-06 | 希尔氏宠物营养品公司 | 提高老年动物的生活质量的方法 |
US20130082232A1 (en) | 2011-09-30 | 2013-04-04 | Unity Semiconductor Corporation | Multi Layered Conductive Metal Oxide Structures And Methods For Facilitating Enhanced Performance Characteristics Of Two Terminal Memory Cells |
MX2007014502A (es) | 2005-05-26 | 2008-02-07 | Metabasis Therapeutics Inc | Tiromimeticos para el tratamiento de enfermedades del higado graso. |
CA2606498C (en) * | 2005-05-26 | 2016-08-09 | Metabasis Therapeutics, Inc. | Novel phosphinic acid-containing thyromimetics |
US7818866B2 (en) * | 2005-05-27 | 2010-10-26 | Prairie Packaging, Inc. | Method of reinforcing a plastic foam cup |
US7694843B2 (en) * | 2005-05-27 | 2010-04-13 | Prairie Packaging, Inc. | Reinforced plastic foam cup, method of and apparatus for manufacturing same |
US7552841B2 (en) * | 2005-05-27 | 2009-06-30 | Prairie Packaging, Inc. | Reinforced plastic foam cup, method of and apparatus for manufacturing same |
US7814647B2 (en) * | 2005-05-27 | 2010-10-19 | Prairie Packaging, Inc. | Reinforced plastic foam cup, method of and apparatus for manufacturing same |
US7536767B2 (en) * | 2005-05-27 | 2009-05-26 | Prairie Packaging, Inc. | Method of manufacturing a reinforced plastic foam cup |
US7704347B2 (en) * | 2005-05-27 | 2010-04-27 | Prairie Packaging, Inc. | Reinforced plastic foam cup, method of and apparatus for manufacturing same |
RU2377980C2 (ru) | 2005-08-17 | 2010-01-10 | Хилл`С Пет Ньютришн, Инк. | Способы и композиции для профилактики и лечения заболеваний почек |
AU2006283371A1 (en) * | 2005-08-26 | 2007-03-01 | Antisoma Research Limited | Combinations comprising DMXAA for the treatment of cancer |
ES2624554T3 (es) | 2005-12-28 | 2017-07-14 | Vertex Pharmaceuticals Incorporated | Formas sólidas de n- [2,4 - bis (1,1 - dimetiletil) - 5 - hidroxifenil] - 1,4 - dihidro - 4 - oxoquinolina - 3 - carboxamida |
US20080161279A1 (en) * | 2006-12-21 | 2008-07-03 | Wisler Gerald L | Methods of Treating Obesity |
PL2136801T3 (pl) * | 2007-03-30 | 2013-01-31 | Tioga Pharmaceuticals Inc | Agoniści kappa-opioidów do leczenia zespołu jelita drażliwego w postaci zmiennej i z dominującą biegunką |
CN101475984A (zh) | 2008-12-15 | 2009-07-08 | 江苏命码生物科技有限公司 | 一种非小细胞肺癌检测标记物及其检测方法、相关生物芯片和试剂盒 |
CA2756031C (en) | 2009-03-20 | 2018-01-02 | Vertex Pharmaceuticals Incorporated | Process for making modulators of cystic fibrosis transmembrane conductance regulator |
WO2011028642A1 (en) * | 2009-09-04 | 2011-03-10 | University Of Louisville Research Foundation, Inc. | Genetic determinants of prostate cancer risk |
EP3150721B1 (de) * | 2009-12-24 | 2019-05-15 | Micromedmark Biotech Co., Ltd | Marker für pankreaskarzinom und nachweisverfahren |
WO2011158667A1 (ja) * | 2010-06-16 | 2011-12-22 | 国立大学法人浜松医科大学 | 大腸腫瘍の検出方法 |
WO2012006088A1 (en) * | 2010-06-29 | 2012-01-12 | University Of Medicine And Dentistry Of New Jersey | Method and kit for classifying a patient |
US9487825B2 (en) | 2011-05-13 | 2016-11-08 | Mount Sinai School Of Medicine | Pooled adapter strategy for reducing bias in small RNA characterization |
US8778843B1 (en) * | 2011-08-03 | 2014-07-15 | Fry Laboratories, L.L.C. | Semi-pan-protozoal by quantitative PCR |
AU2012294570B2 (en) * | 2011-08-05 | 2015-09-10 | Gen-Probe Incorporated | Antiandrogen therapy monitoring methods and compositions |
US20130035257A1 (en) * | 2011-08-05 | 2013-02-07 | University Of British Columbia | Microfluidic arrays and methods for their preparation and use |
WO2013089882A2 (en) * | 2011-09-27 | 2013-06-20 | The Regents Of The University Of Michigan | Recurrent gene fusions in breast cancer |
US9970060B2 (en) * | 2011-11-23 | 2018-05-15 | Medical Diagnostic Laboratories, Llc | Quantitation and profiling of vaginal microflora |
EP2794854B1 (de) * | 2011-12-23 | 2018-06-20 | DePuy Synthes Products, Inc. | Nachweis von zellen aus menschlichem nabelschnurgewebe |
BR112014021090B1 (pt) | 2012-02-27 | 2023-01-24 | Vertex Pharmaceuticals Incorporated | Composição farmacêutica e uso de n-[2,4-bis(1,1-dimetiletil)-5-hidróxifenil]-1,4-di-hidro-4-oxoquinolina3-carboxamida na preparação da mesma |
US10154988B2 (en) | 2012-11-14 | 2018-12-18 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
US20140221424A1 (en) * | 2013-01-30 | 2014-08-07 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions for use in the treatment of cystic fibrosis |
US8987327B1 (en) | 2013-10-11 | 2015-03-24 | Eugene Lipov | Kits and methods for treating post traumatic stress disorder (PTSD) and hot flashes |
WO2016057730A1 (en) | 2014-10-07 | 2016-04-14 | Strohmeier Mark | Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator |
WO2016196229A1 (en) | 2015-06-01 | 2016-12-08 | Cellular Research, Inc. | Methods for rna quantification |
CN109072288A (zh) * | 2016-05-02 | 2018-12-21 | 赛卢拉研究公司 | 精确的分子条形编码 |
EP3541395A4 (de) | 2016-11-21 | 2020-07-01 | Viking Therapeutics, Inc. | Verfahren zur behandlung einer glykogenspeicherkrankheit |
EA201992703A1 (ru) | 2017-06-05 | 2020-04-15 | Вайкинг Терапьютикс, Инк. | Композиции для лечения фиброза |
EP3728636A1 (de) | 2017-12-19 | 2020-10-28 | Becton, Dickinson and Company | Mit oligonukleotiden assoziierte teilchen |
EA202091979A1 (ru) | 2018-03-22 | 2021-06-22 | Вайкинг Терапьютикс, Инк. | Кристаллические формы и способы получения кристаллических форм соединения |
US11371076B2 (en) | 2019-01-16 | 2022-06-28 | Becton, Dickinson And Company | Polymerase chain reaction normalization through primer titration |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4069343A (en) | 1973-03-23 | 1978-01-17 | American Home Products Corporation | Oxamic acid derivatives for the prevention of immediate type hypersensitivity reactions |
US4554290A (en) | 1983-06-17 | 1985-11-19 | Ciba-Geigy Corporation | Oxamic acid derivatives |
US5061798A (en) | 1985-01-18 | 1991-10-29 | Smith Kline & French Laboratories, Ltd. | Benzyl pyridyl and pyridazinyl compounds |
GB8501372D0 (en) | 1985-01-18 | 1985-02-20 | Smith Kline French Lab | Chemical compounds |
US5232947A (en) | 1988-07-04 | 1993-08-03 | Meiji Seika Kaisha, Ltd. | Oxamic acid compounds and pharmaceutical composition for use in improvement of damaged cerebral functions of brain |
US5284971A (en) | 1992-07-16 | 1994-02-08 | Syntex (U.S.A.) Inc. | 4-(3-cyclohexyl-4-hydroxy or-methoxy phenylsulfonyl) 3,5 dibromo phenyl acetic thyromimetic cholesterol-lowering agents |
DK0580550T3 (da) | 1992-07-21 | 1998-02-02 | Ciba Geigy Ag | Oxamidsyrederivater som hypercholesterolæmiske midler |
-
2000
- 2000-02-14 DK DK00301104T patent/DK1033364T3/da active
- 2000-02-14 DE DE60018225T patent/DE60018225T2/de not_active Expired - Fee Related
- 2000-02-14 PT PT00301104T patent/PT1033364E/pt unknown
- 2000-02-14 AT AT00301104T patent/ATE289586T1/de not_active IP Right Cessation
- 2000-02-14 ES ES00301104T patent/ES2234523T3/es not_active Expired - Lifetime
- 2000-02-14 EP EP00301104A patent/EP1033364B1/de not_active Expired - Lifetime
- 2000-02-28 BR BR0000968-7A patent/BR0000968A/pt not_active Application Discontinuation
- 2000-02-28 US US09/514,696 patent/US6194454B1/en not_active Expired - Fee Related
- 2000-02-28 CA CA002299760A patent/CA2299760C/en not_active Expired - Fee Related
- 2000-02-29 JP JP2000052907A patent/JP3564680B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP1033364B1 (de) | 2005-02-23 |
DK1033364T3 (da) | 2005-06-06 |
DE60018225D1 (de) | 2005-03-31 |
BR0000968A (pt) | 2000-09-19 |
US6194454B1 (en) | 2001-02-27 |
JP2000256299A (ja) | 2000-09-19 |
PT1033364E (pt) | 2005-07-29 |
CA2299760C (en) | 2006-01-10 |
JP3564680B2 (ja) | 2004-09-15 |
DE60018225T2 (de) | 2005-12-29 |
EP1033364A1 (de) | 2000-09-06 |
CA2299760A1 (en) | 2000-09-01 |
ES2234523T3 (es) | 2005-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE289586T1 (de) | Oxamsäuren mit einer cyanogruppe als liganden für den thyroidrezeptor | |
DK1088819T3 (da) | 6-azauracilderivater som thyroidreceptorligander | |
AP2001002259A0 (en) | Oxamic acids and derivatives as thyroid receptor ligands. | |
BR0101527A (pt) | Ligandos de receptores de tiróide | |
HUP0402236A2 (hu) | Heterociklusos vegyületek, az ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
EA200200921A1 (ru) | Полуамиды малоновой кислоты и их производные в качестве лигандов тиреоидных рецепторов | |
ATE313325T1 (de) | Indolcaroboxylsäure als thyroidrezeptor-liganden | |
CA2332066A1 (en) | Tetrazole compounds as thyroid receptor ligands | |
ATE330930T1 (de) | Neue ethylaminderivate | |
NO20002589D0 (no) | Bifenylamidinderivater | |
DK0902018T3 (da) | 2-(arylpheny)amino-imidazolinderivater | |
ATE245141T1 (de) | Benzolsulfonamidderivate | |
NO178397C (no) | Substituerte 1,2,3,4-tetrahydrocyklopent[bÅindoler, 1,2,3,3a,4,8a-heksahydrocyklopent[bÅindoler og beslektede forbindelser, mellomprodukter og deres bruk som medikamenter | |
PT816353E (pt) | Novos derivados de coumarina, processos para a sua preparacao e sua utilizacao | |
ES533657A0 (es) | Un procedimiento para la preparacion de nuevos derivados de pirrolo-(2,1-a)isoquilonina. | |
ES2085540T3 (es) | 2-(3-fenilpropil)hidrazinas, productos intermedios en y un procedimiento para la preparacion de las mismas, y su uso como medicamentos. | |
BR0007593A (pt) | Processo para preparar uma aza-macrolida com 4"(r)-nh2" |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1033364 Country of ref document: EP |
|
REN | Ceased due to non-payment of the annual fee |